Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
Access to genomic testing, not therapy cost, is the biggest challenge
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
Harnessing advanced data analysis for early detection, prevention and better outcomes
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Bridging the gap between histopathology and molecular pathology
The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
The decision was driven by results from the Phase III CAPItello-281 trial,
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
